On Dec. 6, 2021, Roche announced that the European Medicines Agencyﾒs Committee for Medicinal Products for Human Use had recommended extending the marketing authorisation for Actemraﾮ/RoActemraﾮ (tocilizumab) to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.